Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.
Authors
Piotr Rutkowski
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland
Piotr Rutkowski, Enriqueta Felip, Victor Moreno, Jose Manuel Trigo Perez, Aitana Calvo, Dariusz Kowalski, Diego Cortinovis, James J. Lee, George Manikhas, Elizabeth Ruth Plummer, Michele Maio, Paolo Antonio Ascierto, Vladimir Ivanovich Vladimirov, Dana Gaffney, Lilian Y. Li, Kyounghwa Bae, James G. Greger, Chu Ri Shin, Hong Xie, Emiliano Calvo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02908906
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 31)
DOI
10.1200/JCO.2019.37.8_suppl.31
Abstract #
31
Poster Bd #
B10
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.
First Author: Victor Moreno
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long
Poster
2019 ASCO Annual Meeting
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
First Author: Georgina V. Long
Poster
2013 ASCO Annual Meeting
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
First Author: Joseph Grosso